Why Context Is the Real Competitive Advantage in Life Sciences

Joe Luminello has spent 20-plus years in life sciences, moving from pharmaceutical sales leadership to a U.S. affiliate of Takeda, then into the startup world co-founding oncology companies, building a Midwest life sciences incubator, and eventually landing somewhere he didn't expect: competitive intelligence.

He founded RCG Intel in late 2023 with a colleague of 30 years. They'd always wanted to build something together. They did. Then his co-founder left to become the CEO of a publicly traded company. "Typical startup fashion," Joe laughed when we talked on the podcast. "You just go with the flow."

So Joe kept building, and it's turned into something he genuinely loves. I sat down with him on From Lab to Launch to talk about what competitive intelligence actually means in practice, how he thinks about AI, and what's making life so complicated for his clients right now.

What RCG Intel actually does

The easiest way Joe has heard the work described: imagine hiring an investigative reporter and sending them to peel back the onion on a specific question. Not to write a column, not to summarize a press release, but to keep digging until there's something you can actually make a decision with.

That's what RCG Intel does, either on a retainer basis or as one-off engagements. Their clients use the intelligence for strategic planning, pricing decisions, pipeline assumptions, supply decisions. Anywhere a knowledge gap could mean an expensive mistake.

Joe used a great scene from The Imitation Game to explain why context matters so much. The team at Bletchley Park had been staring at intercepted German messages forever, unable to crack the cipher. The breakthrough came in a pub, when someone casually mentioned that every single German message started the same way. That tiny human observation unlocked the entire puzzle. The data was always there. What was missing was someone asking the right question from the right angle.

"Data without context is just data," I said to him. He agreed immediately. That's the business.

Why they chose people over AI

One of the most interesting strategic choices Joe made early on was figuring out what not to do.

He pushed the team hard on AI, week after week, for months. What's our AI play? Do we need to build something? Do we need to buy something? Eventually they worked through it and came out the other side with a clear answer: they don't need to out-build Anthropic or OpenAI. They can't, and that's fine.

What RCG Intel has instead is relationships. With commercial scientists, MDs, business leaders across the industry. Those relationships let them take raw data and apply the kind of context you simply don't get from reading a conference abstract or running a query. The human interpretation, built on decades of lived experience, is the product.

So they hire accordingly. People with eight or more years of experience, ideally folks who've worked on the client side, because those are the people who can anticipate not just what the data says but what questions it's going to generate inside a boardroom.

For life science companies thinking about their own AI strategy, it's a useful model to think about. The tool matters a lot less than the judgment layer on top of it.

What's keeping clients up at night

I asked Joe what the biggest challenge facing his clients is right now, and he was direct: everything is happening at once, and it's happening fast.

Tariffs. Most-favored-nation pricing pressure. Supply chain uncertainty. AI adoption decisions that feel urgent but aren't always clear. The traditional planning rhythm, where you spend the summer building your strategy and finalize it in the fall for the following year, doesn't really fit the pace of change anymore. "Then February comes," Joe said, "and everything's upside down."

The result is a kind of market-wide inertia. Not panic, but paralysis. Leaders who know they need to move but aren't sure which direction. And in that environment, good intelligence isn't a nice-to-have. It's what helps you pick a direction with some confidence.

This challenge isn't unique to Joe's clients. For early-stage biotech and pharma companies especially, the ability to make well-informed strategic calls is often the difference between a runway that lasts and one that doesn't.

A nuanced take on AI adoption

Joe is not an AI skeptic. He wrote a book about it. But his message to leaders is: be deliberate. Don't react. Don't chase.

He recently reposted a headline urging companies to pump the brakes on AI, and it got more impressions than anything he'd ever published. "I think everyone wants permission to slow down," he said. "And it's okay. You're not going to miss the boat."

The deeper concern he has is one that doesn't get talked about enough: if companies start using AI to replace junior employees rather than training those employees to eventually become senior ones, they're quietly dismantling the very institutional knowledge that makes their AI outputs worth anything.

When your senior people leave, who's doing the quality check? And if the answer is nobody, what are you left with?

It connects to something Joe said about the nature of AI replacing work versus replacing occupations. "You're not moving from one job to another," he said. "You're removing that occupation from play entirely. And that's very different." It's worth sitting with, especially in an industry where the contextual expertise that makes someone genuinely useful takes a decade to build.

For biotech organizations navigating compliance and quality work, that same principle applies: the tools are only as good as the people interpreting and acting on them.

Advice for aspiring life science entrepreneurs

Joe's advice here was grounded and honest, which I appreciated.

If you have the pedigree, the network, and you're near the capital pools in Boston or the Bay Area, the development side of pharma is a high-risk, high-reward bet that can be worth taking. For everyone else, the services, devices, diagnostics, and AI-adjacent opportunities offer more accessible paths with less capital burn. (And if you're trying to figure out where to plant roots, the geography still matters a lot.)

"There's going to be plenty of things to do," he said. "Some AI will take out jobs, but some AI will generate more, at least in the short term."

The bigger point he kept coming back to: plan the work and work the plan. Build toward something. Don't just react to the next shiny thing or the next headline. The sun comes up tomorrow no matter what dropped on Twitter this morning.

Where to find Joe

Joe is active on LinkedIn and posts regularly on competitive intelligence, AI strategy, and life sciences leadership. His book walks through RCG Intel's own AI decision-making process alongside broader examples from Netflix to how Huntsville, Alabama became America's rocket capital. It's on Amazon.

You can learn more about what they do at rcgintel.com.

Listen to this episode and every past episode of From Lab to Launch at qualio.com/from-lab-to-launch-podcast. If you enjoy the show, a review on Apple Podcasts or Spotify goes a long way in helping more people in the life sciences community find us.